Apo2L/TRAIL and its death and decoy receptors

被引:726
|
作者
LeBlanc, HN [1 ]
Ashkenazi, A [1 ]
机构
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
来源
CELL DEATH AND DIFFERENTIATION | 2003年 / 10卷 / 01期
关键词
apoptosis; caspases; TNF superfamily; Bcl-2; bax;
D O I
10.1038/sj.cdd.4401187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apo2 ligand or tumour necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is one of the several members of the tumour necrosis factor (TNF) gene superfamily that induce apoptosis through engagement of death receptors (DRs). Apo2L/TRAIL interacts with an unusually complex receptor system of two DRs and three decoys. This protein has garnered intense interest as a potential candidate for cancer therapy because as a trimer it selectively induces apoptosis in many transformed cells but not in normal cells. While much of the early characterisation of Apo2L/TRAIL and its receptors relied on overexpression studies, recent work using untransfected cells has clarified how endogenous proteins transmit apoptotic signals from this ligand. In this review, we focus on the apoptotic signalling pathways stimulated by Apo2L/TRAIL and summarise what is known about its physiological role.
引用
收藏
页码:66 / 75
页数:10
相关论文
共 50 条
  • [1] Apo2L/TRAIL and its death and decoy receptors
    H N LeBlanc
    A Ashkenazi
    Cell Death & Differentiation, 2003, 10 : 66 - 75
  • [2] Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Holland, Pamela M.
    CANCER LETTERS, 2013, 332 (02) : 156 - 162
  • [3] Apo2L/TRAIL and immune regulation
    Anel, Alberto
    Bosque, Alberto
    Naval, Javier
    Pineiro, Andres
    Larrad, Luis
    Angeles Alava, Maria
    Jose Martinez-Lorenzo, Maria
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 2074 - 2084
  • [4] Human recombinant TRAIL/Apo2L and agonistic monoclonal antibodies to TRAIL death receptors from the laboratory to the clinic.
    de Vries, EGE
    Gietema, JA
    de Jong, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9175S - 9175S
  • [5] Death to the bad guys: Targeting cancer via Apo2L/TRAIL
    S. Bouralexis
    D. M. Findlay
    A. Evdokiou
    Apoptosis, 2005, 10 : 35 - 51
  • [6] Death to the bad guys: Targeting cancer via Apo2L/TRAIL
    Bouralexis, S
    Findlay, DM
    Evdokiou, A
    APOPTOSIS, 2005, 10 (01) : 35 - 51
  • [7] A novel receptor for Apo2L/TRAIL contains a truncated death domain
    Marsters, SA
    Sheridan, JP
    Pitti, RM
    Huang, A
    Skubatch, M
    Baldwin, D
    Yuan, J
    Gurney, A
    Goddard, AD
    Godowski, P
    Ashkenazi, A
    CURRENT BIOLOGY, 1997, 7 (12) : 1003 - 1006
  • [8] Identification of genes affecting Apo2L/TRAIL sensitivity and resistance in an Apo2L/TRAIL resistant chondrosarcoma cell line
    Remillard, Stephen
    Solomon, Sarah
    Zhang, Yixiang
    Demetri, George
    Wagner, Andrew
    CANCER RESEARCH, 2009, 69
  • [9] Human recombinant TRAIL/Apo2L and trail agonistic antibodies
    de Vries, EGE
    Gietema, JA
    de Jong, S
    ANNALS OF ONCOLOGY, 2005, 16 : 23 - 23
  • [10] Autophagy as a mechanism of Apo2L/TRAIL resistance
    Sharma, Arishya
    Almasan, Alexandru
    CANCER BIOLOGY & THERAPY, 2018, 19 (09) : 755 - 762